Status and phase
Conditions
Treatments
About
This study evaluates the dose response of ACT-541468 on the change of WASO from baseline to Days 1 and 2, assessed by PSG.
Full description
This study consists of the following phases: screening phase; double-blind treatment phase; safety follow-up phase. Safety is monitored throughout the study.
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Principal inclusion Criteria:
Principal exclusion Criteria:
Primary purpose
Allocation
Interventional model
Masking
360 participants in 6 patient groups, including a placebo group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal